SHFS vs LGND

For growth investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger pick with 27.

3% revenue growth year-over-year, versus -9. 2% for SHF Holdings, Inc. (SHFS). Analysts rate Ligand Pharmaceuticals Incorporated (LGND) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ligand Pharmaceuticals Incorporated (LGND) delivered a total return of +61.

0%, compared to -99. 8% for SHF Holdings, Inc. (SHFS). Over 10 years, the gap is even starker: LGND returned +73. 0% versus SHFS's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ligand Pharmaceuticals Incorporated (LGND) is the lower-risk stock at 0.

99β versus SHF Holdings, Inc. 's 1. 87β — meaning SHFS is approximately 89% more volatile than LGND relative to the S&P 500.

By revenue growth (latest reported year), Ligand Pharmaceuticals Incorporated (LGND) is pulling ahead at 27.

3% versus -9. 2% for SHF Holdings, Inc. (SHFS). On earnings-per-share growth, the picture is similar: Ligand Pharmaceuticals Incorporated grew EPS -107. 5% year-over-year, compared to -114. 7% for SHF Holdings, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ligand Pharmaceuticals Incorporated (LGND) is the more profitable company, earning -2.

4% net margin versus -262. 5% for SHF Holdings, Inc. — meaning it keeps -2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LGND leads at -13. 5% versus -24. 2% for SHFS. At the gross margin level — before operating expenses — SHFS leads at 104. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

99)). SHF Holdings, Inc. (SHFS) carries a higher beta of 1. 87 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LGND: +73. 0%, SHFS: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SHFS (Financial Services) and LGND (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SHFS is a small-cap quality compounder stock; LGND is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.